RNA as drug and antidote.
Tuddenham
Edward
E
D000925:Anticoagulants / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology*; D000931:Antidotes / Q000378:metabolism / Q000494:pharmacology*; D000075202:Contraindications; D015195:Drug Design; D015949:Factor IXa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015944:Factor VIIIa / Q000378:metabolism; D005170:Factor X / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D006494:Heparin Antagonists / Q000494:pharmacology; D006801:Humans; D009843:Oligoribonucleotides / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D012313:RNA / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D013379:Substrate Specificity; D013917:Thrombin / Q000378:metabolism; D013921:Thrombocytopenia / Q000139:chemically induced
D000925:Anticoagulants; D000931:Antidotes; D006494:Heparin Antagonists; D009843:Oligoribonucleotides; D012313:RNA; D015944:Factor VIIIa; D005170:Factor X; D006493:Heparin; D015949:Factor IXa; D013917:Thrombin